Jin-Bo Gou

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Scott A. Halperin, Lingyun Ye, Donna MacKinnon‐Cameron et al. · The Lancet · 2021 · 230 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +8

Safety and Immunogenicity of a Recombinant Adenovirus Type-5–Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

Fengcai Zhu, Pengfei Jin, Tao Zhu et al. · Clinical Infectious Diseases · 2021 · 102 citations · Full text

Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial

Rong Tang, Hui Zheng, Busen Wang et al. · The Lancet Respiratory Medicine · 2023 · 48 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial

Jingxin Li, Lihua Hou, Jin-Bo Gou et al. · The Lancet Infectious Diseases · 2023 · 47 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +9

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial

Lairun Jin, Rong Tang, Shipo Wu et al. · Emerging Microbes & Infections · 2022 · 29 citations · Full text